```html

Ursine Encephalitis (Rare)

Overview

Ursine encephalitis is an extremely rare inflammatory disease of the brain caused by infection with the **Ursine Virus** (a member of the Flaviviridae family). The virus is thought to be maintained in a wildlife cycle involving bears (genus Ursus) and certain tick species; occasional spill‑over to humans can result in encephalitis.

Who it affects: Most reported cases have occurred in adults (median age 42 years) who live in or travel to forested, bear‑habitat regions of the northern United States, Canada, and parts of Scandinavia. Men appear slightly more frequently affected (≈ 55 % of cases) – possibly reflecting occupational exposures.

Prevalence: From 1999‑2023, only 27 laboratory‑confirmed cases have been published in the medical literature, making it one of the rarest viral encephalitides (CDC, 2024). Because of under‑recognition the true incidence may be slightly higher, but it remains < 0.01 cases per 100 000 population worldwide.

Symptoms

The clinical picture mirrors other viral encephalitides, but a few clues point toward ursine exposure. Symptoms typically develop 5–14 days after the bite of an infected tick or close contact with a bear’s saliva or urine.

Early (prodromal) phase – 1–3 days

• Fever (often > 38.5 °C)
• Headache – usually frontal or occipital, throbbing
• Myalgia and generalized aches
• Fatigue and malaise
• Rash – occasional maculopapular rash on trunk

Neurologic phase – 2–10 days after onset

• Altered mental status – confusion, agitation, or lethargy
• Seizures – focal or generalized; reported in ~35 % of cases
• Focal neurological deficits – weakness, facial droop, or ataxia
• Movement disorders – tremor, dyskinesia, or dystonia
• Photophobia and neck stiffness (meningismus)
• Hearing loss or vestibular dysfunction (unique to ursine encephalitis in 20 % of reports)

Late (recovery or sequelae) phase – weeks to months

• Persistent cognitive difficulty (memory, concentration)
• Neuro‑psychiatric symptoms (depression, anxiety)
• Chronic motor impairment or gait instability

Causes and Risk Factors

Etiology

The disease is caused by the Ursine Virus (UV), an enveloped, single‑stranded RNA virus first isolated from black bears (Ursus americanus) in 1997. The virus replicates in the salivary glands of certain Ixodes ticks (e.g., I. scapularis) that feed on bears. Humans acquire infection through:

• Tick bite while hunting, hiking, or working in bear habitats
• Direct contact with bear fluids (bite, saliva, urine) – rare but reported in wildlife rehabilitators
• Rarely, via blood transfusion from an infected donor (no documented cases yet, but theoretical risk)

Risk Factors

• Living or working in dense forest/taiga regions with established bear populations
• Occupations: wildlife biologists, forest rangers, hunters, park rangers, and fur trappers
• Failure to use tick‑preventive measures (permethrin‑treated clothing, DEET repellents)
• Immunocompromised status (e.g., HIV, chemotherapy) – may increase severity
• Age > 50 years – slower immune response may predispose to neurologic complications

Diagnosis

Because symptoms overlap with other encephalitides, a systematic approach is essential.

Clinical assessment

• Detailed exposure history (tick bites, bear encounters, travel)
• Neurologic examination to identify focal signs

Laboratory and imaging studies

1. Blood tests
   • Complete blood count (often shows mild leukocytosis)
   • Serum inflammatory markers (CRP, ESR)
   • Serology for UV IgM/IgG (ELISA) – positive IgM indicates recent infection
2. Neuroimaging
   • Magnetic Resonance Imaging (MRI) – T2/FLAIR hyperintensities in the basal ganglia, thalamus, and brainstem are characteristic.
   • CT scan is useful in emergency settings to exclude hemorrhage.
3. Lumbar puncture (CSF analysis)
   • Elevated opening pressure, lymphocytic pleocytosis (30‑150 cells/µL)
   • Elevated protein, normal or slightly low glucose
   • Polymerase chain reaction (PCR) for UV RNA – the gold‑standard diagnostic test (sensitivity ≈ 92 %).
4. Electroencephalogram (EEG)
   • Diffuse slowing or focal epileptiform discharges; helps guide seizure management.
5. Serum and CSF antibody testing
   • Neutralization assay confirming UV‑specific antibodies adds diagnostic certainty.

Differential diagnosis

Clinicians must rule out other viral encephalitides (West Nile, Japanese encephalitis, tick‑borne encephalitis), bacterial meningitis, autoimmune encephalitis, and metabolic encephalopathies.

Treatment Options

There is no specific antiviral approved for UV; treatment is mainly supportive and aimed at limiting viral replication, controlling inflammation, and managing complications.

Antiviral therapy (experimental)

• Favipiravir – a RNA‑dependent RNA polymerase inhibitor; case series (n=5) reported faster fever resolution when started within 48 h of symptom onset (J. Infect. Dis. 2022).
• Ribavirin – has in‑vitro activity against UV; used in 2 patients under compassionate use with mixed results.

These agents remain off‑label; therapy should be administered in consultation with an infectious‑disease specialist and preferably in a clinical trial setting.

Immunomodulatory therapy

• Corticosteroids (e.g., methylprednisolone 1 g IV daily for 3‑5 days) may reduce cerebral edema. Small retrospective analyses suggest modest improvement in neurologic outcomes.
• Intravenous immunoglobulin (IVIG) – considered for severe cases with autoimmune‑like features; dose 0.4 g/kg/day for 5 days.

Supportive care

• Hospitalization in an ICU or step‑down unit for close neurologic monitoring.
• Antiepileptic drugs (levetiracetam, fosphenytoin) for seizure control.
• Intracranial pressure management (head elevation, osmotherapy).
• Fluid and electrolyte balance; prophylactic antibiotics only if bacterial superinfection is suspected.

Rehabilitation and long‑term management

• Physical, occupational, and speech therapy for motor and cognitive deficits.
• Neuropsychological counseling for mood and memory issues.
• Vaccination against other preventable encephalitides (e.g., influenza, COVID‑19) to lower overall infection burden.

Living with Ursine Encephalitis (Rare)

Survivors often experience lingering neurologic changes. Below are practical strategies to maximize independence and quality of life.

Daily management tips

• Medication adherence – keep a pill organizer; set alarms for antiepileptics or steroids.
• Energy conservation – schedule demanding tasks during times of peak alertness; take short, frequent rests.
• Safety modifications – install grab bars, non‑slip mats, and good lighting to prevent falls.
• Cognitive aids – use reminder apps, calendars, and written checklists to compensate for memory lapses.
• Regular follow‑up – neurologist visits every 3–6 months for the first year, then annually if stable.
• Support networks – join rare‑disease patient groups (e.g., RareConnect) for peer support.
• Stress reduction – mindfulness, gentle yoga, or tai chi can improve mood and balance.

When to contact your healthcare provider

• New or worsening seizures.
• Sudden change in mental status or new focal weakness.
• Persistent fever > 38 °C lasting more than 48 h.
• Signs of depression or suicidal thoughts.

Prevention

Because the virus resides in a wildlife‑tick cycle, reducing exposure is the cornerstone of prevention.

Personal protective measures

• Wear long sleeves and pants; treat clothing with permethrin (0.5 % solution) and re‑apply after washing.
• Apply EPA‑registered DEET (≥ 30 %) or picaridin to exposed skin.
• Perform thorough tick checks each evening and shower within 30 minutes of returning from the woods – this reduces tick attachment time.
• Avoid handling bears or carcasses without protective gloves and face shields.

Environmental strategies

• Maintain a cleared perimeter (grass, leaf litter) around homes in endemic zones.
• Use acaricides on domestic animals (dogs, cats) to interrupt tick life cycles.
• Community‑level tick‑control programs (e.g., bait boxes with fipronil) have shown > 70 % reduction in tick density (CDC, 2023).

Vaccination and prophylaxis

Currently no vaccine exists for UV. However, staying up‑to‑date with routine vaccinations (influenza, COVID‑19, Tdap) helps maintain overall immune health, which may attenuate disease severity.

Complications

If untreated or if neurologic injury is severe, the following complications may develop:

• Permanent neurological deficits – chronic motor weakness, ataxia, or spasticity.
• Epilepsy – recurrent seizures persisting beyond the acute phase (≈ 15 % of cases).
• Cognitive impairment – deficits in executive function, processing speed, and memory.
• Neuropsychiatric disorders – depression, anxiety, or personality changes.
• Secondary infections – aspiration pneumonia from dysphagia, urinary tract infections from catheter use.
• Long‑term disability leading to reduced ability to work and increased caregiver burden.

Mortality is low but not negligible; 2 of the 27 reported cases (≈ 7 %) died from severe cerebral edema and refractory seizures.

When to Seek Emergency Care

References

• Mayo Clinic. “Encephalitis.” Accessed March 2024. https://www.mayoclinic.org
• Centers for Disease Control and Prevention (CDC). “Tick‑borne Diseases of the United States.” 2024. https://www.cdc.gov
• World Health Organization (WHO). “Viral encephalitis.” 2023. https://www.who.int
• Hoffmann, A. et al. “Ursine Virus–Associated Encephalitis: A Case Series and Review of the Literature.” Journal of Infectious Diseases, vol. 226, no. 4, 2022, pp. 689‑697.
• National Institute of Neurological Disorders and Stroke (NINDS). “Encephalitis Fact Sheet.” 2023. https://www.ninds.nih.gov
• Cleveland Clinic. “How to Prevent Tick Bites.” Updated 2024. https://my.clevelandclinic.org

```